SamanTree Medical SA

Based in Switzerland, founded in 2014 by Olivier Delporte and headquartered in Lausanne, Switzerland, SamanTree Medical SA specializes in advanced imaging technology that provides real-time tissue assessment for surgical applications, enhancing decision-making in critical healthcare settings. SamanTree Medical SA, founded in 2014 and headquartered in Lausanne, Switzerland, focuses on innovative medical imaging solutions. In January 2026, SamanTree Medical SA raised EUR 20 million in venture debt funding from European Investment Bank. CEO Olivier Delporte oversees the company's strategic direction.

SamanTree Medical specializes in advanced imaging technology for real-time tissue assessment in surgical settings. Their flagship product, the Histolog® Scanner, employs ultra-fast confocal microscopy technology for high-resolution imaging of fresh human tissue specimens. By enabling clinicians to visualize morphological microstructures, the Histolog Scanner supports immediate decision-making at the point of care, addressing critical challenges in cancer diagnosis and treatment. The device facilitates swift scanning of resected tissue samples, providing easy-to-read images in under a minute, which enhances the efficiency of tissue assessment processes.

SamanTree Medical primarily serves healthcare professionals in hospitals and pathology laboratories across Europe and North America, focusing on applications in breast and prostate cancer treatments, as well as dermatology. SamanTree Medical generates revenue through the sale of its innovative imaging solutions, particularly the Histolog® Scanner, which has received CE marking and FDA clearance. The company engages in direct sales to healthcare institutions and collaborates with medical professionals in surgical environments. Revenue transactions typically involve one-time purchases of the Histolog Scanner and related products, such as the Histolog Dip and Histolog Dish.

Additionally, the company may establish partnerships with medical facilities to provide ongoing support, training, and software solutions, ensuring clients can effectively utilize the imaging technology in their procedures. This comprehensive approach facilitates a robust business model focused on delivering value to clinicians and improving patient outcomes in cancer care. The company will use the January 2026 funding to develop its confocal microscopy scanner to support rapid, high‑resolution imaging during surgical procedures.